JL, very interesting, thanks. 2008 illuminated the twisted evils on Wall Street. However, restrictions were short lived and regulations failed to come about to prevent the reasons behind the bank failures. It was like a Doctor telling the patient they are not to cough for 30 days and then failing to treat the underlying pneumonia. Short sellers are alive and well. There are more hedge funds today that there were before many failed post 2008. Their freshest meat exits in the Biotech space (small caps). Though some of AMRNs short position is attributed to debt neutrality, the vast majority exits to exploit Amarin's unfortunate events in the past. They smelled blood and piled on. Here is a good article about naked shorting of biotech companies:
Market Data 
Markets 
AI
